Condition: Malignant Neoplasms of Respiratory and Intrathoracic Organs · Squamous Cell Carcinoma of the Larynx · Sponsor: M.D. Anderson Cancer Center
To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.
This description comes directly from the study's public registry record.
Jack Phan, MD, PHD · 713-563-2300 · jphan@mdanderson.org
Always discuss trial participation with your own doctor first.
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03114462